Gina Woods, MD, shares three case scenarios of sequential treatment decision-making for long-term therapy and discusses research that can inform clinical decisions.

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months. EB613 single ...

Long-lasting treatment suppresses HIV in people with mental illness and other conditions that make it challenging to adhere to standard treatments.

As of Thursday, February 26, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 5.99%, which has investors questioning if this is right time to buy.

Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.

Q4 2025 earnings call recap: ipratropium HFA launch, 2026 revenue guidance, margins, BAQSIMI growth and pipeline updates—read now.

A new technology has been developed to suppress immune rejection, the biggest challenge in organ transplantation, without ...

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

As Washington pushes cheaper medicines through TrumpRx, Mark Cuban challenges the pharmaceutical middlemen, and big pharma pours billions into oral peptide technologies, Entera Bio (NASDAQ:ENTX) is ...

Amphastar Pharmaceuticals is set to report fourth-quarter 2025 results after the market close Thursday, with investors looking for signs the generic drugmaker can translate recent regulatory wins into ...

Scientists at Stanford Medicine have discovered a treatment that can reverse cartilage loss in aging joints and even prevent arthritis after knee injuries. By blocking a protein linked to aging, the ...

Rob Fried, CEO of Niagen Bioscience, commented, “This patent expands our intellectual property for our patented NR ingredient, Niagen ®, into IV and injectable delivery formats. With expected ...